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Dysregulation of MS risk genes and
pathways at distinct stages of disease
ABSTRACT
Objective: To perform systematic transcriptomic analysis of multiple sclerosis (MS) risk genes in
peripheral blood mononuclear cells (PBMCs) of subjects with distinct MS stages and describe the
pathways characterized by dysregulated gene expressions.
Methods: We monitored gene expression levels in PBMCs from 3 independent cohorts for a total
of 297 cases (including clinically isolated syndromes (CIS), relapsing-remitting MS, primary and
secondary progressive MS) and 96 healthy controls by distinct microarray platforms and quanti-
tative PCR. Differential expression and pathway analyses for distinct MS stages were defined
and validated by literature mining.
Results: Genes located in the vicinity of MS risk variants displayed altered expression in peripheral
blood at distinct stages of MS compared with the healthy population. The frequency of dysregu-
lation was significantly higher than expected in CIS and progressive forms of MS. Pathway anal-
ysis for each MS stage–specific gene list showed that dysregulated genes contributed to
pathogenic processes with scientific evidence in MS.
Conclusions: Systematic gene expression analysis in PBMCs highlighted selective dysregulation
of MS susceptibility genes playing a role in novel and well-known pathogenic pathways. Neurol
Neuroimmunol Neuroinflamm 2017;4:e337; doi: 10.1212/NXI.0000000000000337
GLOSSARY
CIS5 clinically isolated syndromes; cRNA5 complementary RNA;DEG5 differentially expressed gene; EAE5 experimental
autoimmune encephalomyelitis; FDR 5 false discovery rate; GWAS 5 genome-wide association studies; HC 5 healthy
control; MHC 5 major histocompatibility complex; MS 5 multiple sclerosis; PBMCs 5 peripheral blood mononuclear cells;
PP-MS 5 primary progressive MS; q-PCR 5 quantitative PCR; RR-MS 5 relapsing-remitting MS; RT-PCR 5 real-time PCR;
SP-MS 5 secondary progressive MS.
MS is an inflammatory demyelinating disease of the CNS with evidence of immune dysfunc-
tion.1 The first clinical episode with features suggestive of MS is classified as clinically isolated
syndrome (CIS), unless lesion dissemination in time and space ratifying MS diagnosis is evi-
denced.2 Approximately, 85% of individuals develop the relapsing-remitting form of MS (RR-
MS), whereas 15% of MS individuals experience a progressive course (primary progressive MS,
PP-MS). After a variable time, most RR-MS subjects advance to a secondary progressive (SP)
phase (SP-MS), where neurologic worsening takes place without periods of remission.3 Several
MS risk variants have been uncovered by genome-wide association studies (GWAS), and many
of them are located close to immunologically relevant genes,4 suggesting that immune dysfunc-
tion may be partly genetically determined. Although effective in highlighting MS risk alleles,
GWAS have failed in dissecting the genetic components of the susceptibility to distinct MS
clinical forms. In fact, MS is a multifactorial disorder determined by the complex interaction
between genetic and environmental factors, whose integration occurs at the epigenetic level and
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determines gene expression. Our group has
recently shown the importance of blood tran-
scriptomics in uncovering gene expression
changes and transcriptional regulators in
MS.5 In this study, we have (1) examined
the expression levels of known MS susceptibil-
ity genes in peripheral blood mononuclear
cells (PBMCs) of CIS, RR-MS, PP-MS, SP-
MS, and control individuals, (2) identified
a panel of blood transcriptional signatures for
distinct MS forms, and (3) explored the path-
ways contributed by the dysregulated suscep-
tibility genes.
METHODS Human subjects and blood sampling. Inves-
tigations were conducted according to the principles expressed in
the Declaration of Helsinki, and peripheral blood was drawn after
signing of the institutional informed consent. We recruited 142
patients with MS (46 CIS, 52 RR-MS, 23 PP-MS, and 21 SP-
MS) and 40 healthy controls (HCs) of Italian origin for the
generation of the main transcriptomic data set by Illumina
platform. Demographic and clinical parameters are shown in
table 1. A second distinct cohort comprising 21 RR-MS, 15
PP-MS, 13 SP-MS, and 27 HCs was enrolled according to the
same inclusion criteria and used for validation with a distinct
array platform (table 1). Finally, a third independent cohort
comprising 31 CIS, 30 RR-MS, 24 PP-MS, 21 SP-MS, and 29
HCs was included and used for validation experiments by
quantitative PCR (q-PCR) (table 1). Patients with MS were
diagnosed according to McDonald criteria6 and were not
suffering from any other acute or chronic inflammatory diseases
or other autoimmune disorders. Furthermore, they had not
started any immunomodulatory therapy for MS yet, as
recruitment was performed over the last 15 years, in a period
when decision to treat was not established and widespread as
nowadays. Blood sampling was performed between 30 and 90
days after the first clinical attack in patients with CIS, and at least
4 weeks after the last clinical attack or steroid treatment for
RR-MS subjects. All participants had peripheral blood counts
within the reference range. All blood samplings were performed
between 9 and 12 AM
PBMC isolation and RNA extraction. PBMCs were isolated
using a discontinuous density gradient (Lymphoprep; Nycomed,
Oslo, Norway). Viable cells were counted by Trypan blue
(Sigma-Aldrich, Milan, Italy) exclusion. Total RNA was extracted
using Tri Reagent (Ambion; Applied Biosystems, Monza, Italy)
and stored at 280°C.
Generation of gene expression data sets. RNA quality was
checked using Bioanalyzer 2100 (Agilent, Milan, Italy). Comple-
mentary RNA (cRNA) synthesis was performed using the Illumi-
na TotalPrep RNA Amplification Kit (Ambion) according to the
manufacturer’s protocol. Hybridization of the cRNA relative to
the first casistics was performed on Illumina Human Ref-8 v2
arrays (Illumina, Son, Netherlands). GenomeStudio GX Software
(Illumina, San Diego, CA) was used to extract the array raw data.
All the raw data were background subtracted by NEC method
and normalized using cubic spline normalization as implemented
in the software. We performed batch correction using COMBAT
to remove batch effects in the PBMC expression data.7 The
second independent transcriptomic data set was generated by
Affymetrix GeneChip Human Genome U133 Plus 2.0 Array.
All the necessary preprocessing steps were performed using
robust multiarray average algorithm present in the Affy package
in Bioconductor and keeping genes with multiple probes as
individual transcripts. The MIAMI compliant microarray data
have been deposited in the EBI ArrayExpress database
Table 1 Subjects demographics and clinical information
HC CIS RR-MS PP-MS SP-MS
Cohort for Illumina arrays
No. (female:male) 40 (20:20) 46 (23:23) 52 (32:20) 23 (09:14) 21 (11:10)
Age, y 33.3 6 10.44 34.0 6 10.17 37.4 6 10.16 52.1 6 11.70 54.3 6 11.10
Disease duration, y — — 7.4 6 6.8 12.41 6 8.58 24.6 6 9.27
EDSS score — — 1.72 6 0.97 5.2 6 2.08 6.7 6 1.3
Cohort for Affymetrix arrays
No. (female:male) 27 (13:14) — 21 (12:09) 15 (09:06) 13 (09:04)
Age, y 42.4 6 9.1 — 41.2 6 8.1 52 6 12.8 41.8 6 9.3
Disease duration, y — — 4.8 6 6.0 15.9 6 8.7 15.4 6 8.0
EDSS score — — 2.3 6 1.1 6.3 6 1.2 5.6 6 1.2
Cohort for q-PCR assays
No. (female:male) 29 (13:16) 31 (19:12) 30 (16:14) 24 (12:12) 21 (15:06)
Age, y 33.7 6 9.31 32.7 6 8.05 36.8 6 8.57 46.7 6 7.96 51.2 6 11.26
Disease duration, y — — 4.4 6 6.2 8.5 6 9.23 18.9 6 6.52
EDSS score — — 1.64 6 0.97 5.15 6 1.54 5.34 6 1.46
Abbreviations: CIS 5 clinically isolated syndrome; EDSS 5 Expanded Disability Status Scale; HC 5 healthy control; MS 5
multiple sclerosis; PP-MS 5 primary progressive MS; RR-MS 5 relapse-remitting MS; q-PCR 5 quantitative PCR; SP-MS 5
secondary progressive MS.
Numbers refer to mean 6 SD.
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(Accession numbers E-MTAB-4890 and E-MTAB-5151).
Probes with a mean intensity value lower than 100 in all
experimental groups were filtered out. Furthermore, we applied
Pearson correlation to identify and remove probes correlating
with age in the healthy population of the Illumina study, where
age ranged from 22 to 57 years. To identify differentially
expressed genes (DEGs) between each clinical form and the
healthy population, we performed a 2-sample t test with
a p value threshold of 0.05. A detailed flow diagram of this
study is depicted in figure 1. To verify whether stage-specific
transcriptomes were enriched in dysregulated risk genes, we
measured the frequency of differential expression of GWAS
genes and compared it to that of DEG in the global
transcriptome by x2 test with Yates’ correction in GraphPad.
Collection of GWAS genes and their mapping to gene
expression data. Genes located in the vicinity of MS suscepti-
bility loci were collected from the supplementary tables 3 and 8
published by the International Multiple Sclerosis Genetics Con-
sortium4 and reporting 48 gene variants from previous GWAS
studies8–10 and 110 non–major histocompatibility complex
(MHC) susceptibility variants described in 2013.4 Figure e-1 at
Neurology.org/nn summarizes the complete list of GWAS genes
considered in our study. To map MS susceptibility genes to the
relative Illumina probe identifiers, all the filtered probes in the
Illumina data set were submitted to DAVID Gene Accession
Conversion Tool,11 using Illumina HumanRef-8 v2 as
a background reference so to retrieve Entrez and gene symbol
identifiers for each probe. The same probe list was submitted
to BioMart ID,12 conversion package in R Bioconductor,13 as
a further control. In this way, gene expression levels were
retrieved for 182 Illumina probes corresponding to 146 GWAS
genes (figure 1). Similarly, GWAS genes were annotated to the
corresponding Affymetrix probes using BioMart ID,12 conversion
package in R Bioconductor,13 and gene expression levels were
retrieved for 344 Affymetrix probes relative to 149 MS
susceptibility genes.
cDNA synthesis and real-time PCR. The purity and the
quality of RNA were analyzed using NanoDrop8000 (Thermo-
Scientific, Waltham, MA). Two-microgram aliquot of total
RNA was reverse transcribed to cDNA using random primers
and Superscript III reverse transcriptase (all from Invitrogen,
Carlsbad, CA) following the manufacturer’s protocol. Real-time
(RT-PCR) was performed using TAQMan Universal Master Mix
(Applied BioSystems). PSMB1 was used as housekeeping gene
based on its low coefficient of variation in the Illumina
transcriptomic data set. Transcript levels of the target gene
CD86 were measured by the TAQMan assay corresponding to
the gene sequence detected by the Illumina probe and expressed
Figure 1 Flow chart of the study
CIS5 clinically isolated syndrome;DEG5 differentially expressedgene; FDR5 false discovery rate; GWAS5 genome-wide association studies; HC5 healthy control;
MS 5 multiple sclerosis; PP-MS 5 primary progressive MS; RR-MS 5 relapsing-remitting MS; RT-PCR 5 real-time PCR; SP-MS 5 secondary progressive MS.
Neurology: Neuroimmunology & Neuroinflammation 3
as percentage of the housekeeping gene. Normality of data
distribution was assessed by Kolmogorov-Smirnov statistics, and
nonparametric Mann-Whitney test was used to compare mean
values. All p values were 2-sided and subjected to a significance
level of 0.05.
Pathway analysis and literature mining. Pathway enrich-
ment analysis was performed starting from the distinct dysregulated
expression profiles isolated in each clinical form of disease. MS spe-
cialty modules in MetaCore (Thomson Reuters, New York, NY)
are manually curated pathways associated with MS pathology,
which are then ranked based on statistical significance. We selected
pathways passing the false discovery rate (FDR)-corrected p value
threshold of 0.05 and containing 3 DEGs and at least 1 GWAS
DEG. For literature mining, PubMed database was used to collect
scientific evidence about the role of the identified biological path-
ways inMS pathogenesis by searching the name of the pathway and
“Multiple Sclerosis” or “EAE.”
RESULTS Transcriptomic analysis in MS. Genes
located in the vicinity of MS susceptibility loci
(hereon called as GWAS genes) were collected from
the supplementary tables 3 and 8 published by the
International Multiple Sclerosis Genetics Consor-
tium4 (see also figure e-1). To examine the expression
levels of the 162 GWAS genes, we generated high-
throughput gene expression data from PBMC of CIS,
RR-MS, PP-MS, SP-MS individuals, and HCs (table 1)
by Illumina arrays, recovered the gene symbols for
GWAS genes, and mapped them to the relative
Illumina probes. As shown in figure 1, there were
72 probes for 68 expressed GWAS genes passing
signal intensity filter. Next, we tested whether these
probes were differentially expressed in any disease
group compared with healthy controls. We observed
29 GWAS DEGs in CIS, 19 in RR-MS, 35 in PP-MS,
and 35 in SP-MS (table 2). Notably, 6 GWAS DEGs
were concordantly dysregulated in all disease groups
compared with HCs, and several other GWAS DEGs
were common to at least 2 MS forms (figure 2A).
Among them, NDFIP1, AHI1, FCRL1, and STAT4
were concordantly regulated in CIS and RR-MS
but not in progressive forms of disease, whereas
11 MS risk genes, including TYK2, IL7R, and
TNFRSF1A, were differentially expressed in PP-MS
and SP-MS but not in CIS and RR-MS subjects
(figure 2A). Finally, some GWAS transcripts were
altered at single stages of disease, suggesting distinct
pathogenic alterations in distinct disease courses
(figure 2A). To verify whether MS transcriptome
was enriched in dysregulated GWAS genes, we
measured the frequency of differential gene
expression in the list of expressed GWAS genes and
in the global transcriptome for each disease subtype
(figure 1, table 2) and verified whether the frequency
of GWAS DEG was significantly higher in the GWAS
gene list than the expected frequency of dysregulation
in a random selection of transcripts using x2 statistics.
As shown in table 2, we found a clear and significant
enrichment of GWAS DEG in CIS, PP-MS, SP-MS,
and not in RR-MS, demonstrating that the frequency
of dysregulation in genes located in the vicinity of MS
susceptibility variants is higher than expected in at least
3 distinct stages of disease. Then, we checked the
expression of the identified GWAS DEG in PBMC
of an independent cohort of subjects including 21 RR-
MS, 15 PP-MS, 13 SP-MS, and 27 HCs, for which
gene expression was generated using the Affymetrix
array platform (table 1). After applying the same
statistical threshold of the Illumina data set, several
dysregulated GWAS DEGs were identified for each
MS form in the Affymetrix data set. In fact, a total
of 26 GWAS DEGs were concordantly upregulated
(or downregulated) compared with the healthy
population in 2 independent transcriptomic data sets
(figure 2B). Finally, we used a third case-control cohort
to validate the expression of CD86, one of the GWAS
genes upregulated in all forms of disease in the
Illumina and Affymetrix data sets, by q-PCR (figures
2C and e-2).
Biological pathways contributed by MS GWAS genes.
To verify whether the dysregulated GWAS genes were
involved in specific biological pathways, we applied the
MetaCore pathway analysis program which uses
a curated annotation database of biological functions
and identifies the significantly enriched pathways for
a given DEG list. Critically considering the limited
Table 2 Probability of GWAS DEG enrichment at distinct stages of MS
GWAS DEG
Expressed
GWAS genes
GWAS
DEG, %
Global
DEG
Expressed
global genes
Global
DEG, % x2 p Value
CIS 29 72 40.2 2,649 10,314 25.68 7.39 0.006
RR-MS 19 72 26.3 2,442 10,314 23.67 0.16 0.686
PP-MS 35 72 48.6 3,487 10,314 33.08 6.44 0.011
SP-MS 35 72 48.6 3,323 10,314 32.21 19.08 0.0001
Abbreviations: CIS 5 clinically isolated syndrome; DEG 5 differentially expressed gene; GWAS 5 genome-wide association
studies; HC 5 healthy control; MS 5 multiple sclerosis; PP-MS 5 primary progressive MS; RR-MS 5 relapsing-remitting
MS; SP-MS 5 secondary progressive MS.
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number of dysregulated GWAS genes for a pathway
analysis, for each disease group, we enriched the list
of GWAS DEG with those dysregulated genes which
were not located in the vicinity of MS susceptibility
variants, performed pathway analysis using the global
DEG list as input, and selected those pathways passing
Figure 2 Dysregulated MS risk genes and pathways at distinct stages of disease
(A) MS susceptibility genes dysregulated at distinct MS stages compared with as measured by Illumina microarrays. (B) Dys-
regulated MS susceptibility genes validated in 2 distinct array platforms. For A and B, fold-change heatmaps represent up-
regulated (red), downregulated (green), and unchanged (gray) expressions in the disease group compared with the healthy
population. (C) Real-time PCR validation of CD86 transcript in peripheral blood mononuclear cells of a third case-control
cohort. Refer also to figure e-2 for data elaboration after removal of a few outliers (samples with expression levels above
500). *p , 0.05, ***p , 0.005. (D) Venn diagram representing number of common and unique enriched pathways for each
disease stage. CIS 5 clinically isolated syndrome; HC 5 healthy control; MS 5 multiple sclerosis; PP-MS 5 primary pro-
gressive MS; RR-MS 5 relapsing-remitting MS; SP-MS 5 secondary progressive MS.
Neurology: Neuroimmunology & Neuroinflammation 5
Table 3 Shared pathways across MS stages
Pathways
FDR p value
PubMed IDCIS RR-MS PP-MS SP-MS
Transcription and translation Regulation of EIF2 activity 0.0161 0.0146 2.97E-04 2.17E-05 15160394
Regulation of EIF4F activity 1.49E-03 2.08E-04 1.43E-03 4.86E-03
CREB pathway 4.58E-03 0.0449 4.30E-03 5.90E-03 11571785
Cell signaling S1P1 receptor signaling via beta-arrestin 8.46E-03 3.33E-03 2.68E-04 4.50E-04
G-protein alpha-12 signaling pathway 2.17E-03 0.0108 9.41E-03 1.71E-03
G-CSF signaling 9.89E-03 9.89E-03 7.47E-04 5.90E-03 25559893
A2A receptor signaling 4.99E-03 0.0255 9.99E-03 2.15E-03 22529293
A3 receptor signaling 0.0219 0.0231 0.0496 1.21E-03 26960979
IP3 signaling 0.0219 0.0449 0.0234 5.87E-04 27378687
Activation of PKC via G-protein–coupled receptor 6.16E-03 0.0307 1.19E-03 6.05E-05 26205402
LTBR1 signaling 0.0143 8.23E-03 9.99E-03 1.34E-03 16870269
IL-33 signaling pathway 1.00E-03 0.0467 0.0304 0.0334 22189043
C5a signaling 2.25E-03 0.0255 0.0124 1.34E-03 19850104
Fc epsilon RI pathway 7.79E-04 5.72E-03 4.72E-03 3.00E-03 11841694
IGF-1 receptor signaling 9.7E-05 2.07E-04 9.7E-06 6.05E-05 24718491
Lipid metabolism_Insulin signaling 0.0176 8.23E-03 5.14E-04 1.47E-04
Receptor-mediated HIF regulation 0.0161 3.18E-03 4.79E-03 6.15E-03 18056737
Insulin regulation of translation 4.47E-03 5.22E-03 5.09E-04 3.99E-04
PTEN pathway 6.82E-03 0.0155 2.55E-04 3.58E-04 18349128
Cell proliferation EGFR signaling pathway 2.68E-04 0.0109 2.68E-04 7.87E-04 26805386
Nucleocytoplasmic transport of CDK/cyclins 4.99E-03 0.0336 0.012 3.58E-03
Erk interactions: inhibition of Erk 0.0215 3.33E-03 6.54E-04 0.0359 16728393
Beta-adrenergic receptors transactivation of EGFR 0.011 0.0278 1.20E-03 0.011 15342205
Cancer Signaling cascades in multiple myeloma cells 5.30E-04 8.37E-03 4.42E-04 1.50E-03
IGF family signaling in colorectal cancer 6.82E-03 8.23E-03 2.55E-04 1.34E-03
Androgen receptor in prostate cancer 0.0132 7.36E-04 5.19E-03 9.46E-04
Ovarian cancer (main signaling cascades) 0.0208 0.0108 0.0326 0.019
Schwann cells transformation in neurofibromatosis 7.86E-04 5.79E-03 1.14E-03 4.50E-04
Prostaglandin E2 in gastric cancer 0.0219 9.89E-03 0.0234 0.0264 23200567
PGE2 pathways in cancer 0.0183 7.40E-04 8.44E-04 3.00E-03 23200567
Cancer independent of coagulation protease 0.0235 0.0466 0.0158 0.0182
Cytoskeleton remodeling TGF, WNT and cytoskeletal remodeling 0.0158 3.6E-05 8.1E-08 3.36E-04
Cytoskeleton remodeling 2.47E-03 2.74E-03 6.54E-04 6.64E-03
FAK signaling 4.99E-03 0.0466 6.59E-03 4.50E-04 27076682
Cell migration C5a-induced chemotaxis 0.0111 0.0255 0.0499 0.012 8994115
Chemokines and adhesion 0.0134 0.0105 0.0135 5.56E-03 25559893
Chemotaxis_Leukocyte chemotaxis 0.0251 2.83E-03 6.99E-03 1.23E-03 25903727
CXCR4 signaling pathway 8.45E-03 0.0415 2.67E-04 6.15E-03 17114479
VEGF signaling via VEGFR2-generic cascades 4.17E-03 9.90E-03 5.77E-04 5.84E-04 12387457
Role of IL-8 in angiogenesis 0.0223 0.012 8.21E-04 6.05E-05 15342208
SDF-1 signaling in hematopoietic stem cell homing 6.13E-03 0.012 3.99E-03 2.14E-03 23192675
Apoptosis Role of PKR in stress-induced apoptosis 9.7E-05 8.23E-03 8.1E-08 3.47E-05 15160394
BAD phosphorylation 1.76E-03 5.45E-04 2.67E-04 1.34E-04 12507784
Continued
6 Neurology: Neuroimmunology & Neuroinflammation
FDR-corrected p value cut-off of 0.05 and containing
3 global DEGs and at least 1 GWAS DEG for each
disease form (figure 1). We found 165, 95, 184, and
223 significant pathways for CIS, RR-MS, PP-MS,
and SP-MS respectively, with 65 pathways shared by
all the disease courses and others common to at least 2
or 3 clinical forms (figure 2D, table e-1). Of interest,
the 65 shared pathways belonged to major biological
themes relative to transcription and translation,
cell signaling and proliferation, cancer, cytoskeleton
remodeling and cell migration, apoptosis, immunity,
and nervous system (table 3). Functions related to
immunity and cell signaling were predominant and
included pathways regulating innate and adaptive
immunity, and triggered by lipids, cytokines, and
growth factors. An interactive link in the table e-1
opens the graphical maps representing the overall
genes and the dysregulated MS transcripts involved
in each pathway. It is important that when searching
for scientific evidence about a role of the pathways in
MS or its animal model by literature mining, we found it
in most cases (table 3). Thus, bioinformatical annotation
of gene expression data led to the identification of a core
of pathogenetic functions common to all MS stages and
characterized by dysregulation in genes including MS
susceptibility genes.
DISCUSSION In this study, we provide evidence that
genes located in the vicinity of MS risk variants display
dysregulated expression in peripheral blood of subjects
with distinct MS stages compared with healthy indi-
viduals, that the frequency of dysregulation is signifi-
cantly higher than expected, and that those genes
contribute to pathogenic pathways in MS.
The most recent Immunochip study has high-
lighted more than 100 novel non-MHC risk variants
in MS and has underlined that several genes close to
the identified polymorphisms play a key role in
immunity, thus suggesting genetic susceptibility to
a dysimmune state.4 On the other hand, genetics
contributes only to part of the risk of developing
MS and has been unsuccessful in determining
Table 3 Continued
Pathways
FDR p value
PubMed IDCIS RR-MS PP-MS SP-MS
Ceramides signaling pathway 7.2E-06 0.0384 3.33E-04 7.40E-03 22544924
Anti-apoptotic action of gastrin 0.0251 0.0255 0.0499 2.15E-03 12507784
HTR1A signaling 4.99E-03 6.43E-03 2.39E-04 6.98E-04
IL-4—antiapoptotic action 1.70E-03 0.0257 0.0171 1.16E-03 23826999
Immunity Inhibitory PD-1 signaling in T cells 4.8E-05 4.37E-03 3.52E-03 4.86E-03 17304234
HSP60 and HSP70/TLR signaling pathway 9.8E-05 0.0372 4.05E-03 2.56E-03 25153885
Immunologic synapse formation 5.37E-04 8.23E-03 3.33E-04 6.11E-04 22312112
ICOS pathway in T-helper cell 1.39E-03 8.23E-03 4.44E-04 3.58E-03 19291374
CD28 signaling 4.58E-03 0.0102 0.0127 0.0295 24412596
IL-15 signaling 9.95E-03 5.31E-04 7.19E-04 0.037 21911607
NFAT in immune response 0.0123 0.0281 4.45E-04 3.58E-03 25630465
TLR2 and TLR4 signaling pathways 4.61E-04 0.0109 2.79E-03 8.36E-03 20434372
BCR pathway 1.73E-03 8.37E-03 7.47E-04 2.94E-04 12244307
IL-2 activation and signaling pathway 4.58E-03 0.045 1.81E-03 0.0131 24376757
MIF the neuroendocrine-macrophage connector 6.82E-03 0.0345 6.65E-03 7.76E-04 23797673
EPO-induced MAPK pathway 6.16E-03 0.0307 0.0304 1.33E-03 17728357
Thrombopoietin-regulated cell processes 6.16E-03 0.0307 0.0135 1.33E-03
Thromboxane A2 signaling pathway 7.86E-04 9.89E-03 3.32E-04 1.21E-03
Nervous system Dynein-dynactin motor complex in axonal transport 0.0347 8.36E-03 0.0206 0.012
Oligodendrocyte precursor cell proliferation 0.0499 0.0307 0.0226 0.0143
Ligand-independent activation of ESR1 and ESR2 0.0143 7.56E-03 8.45E-04 7.09E-03 15161628
CDK5 in neuronal death and survival 0.0499 0.0415 0.0333 0.0156 20937706
Abbreviations: CIS 5 clinically isolated syndrome; MS 5 multiple sclerosis; PP-MS 5 primary progressive MS; RR-MS 5 relapsing-remitting MS;
SP-MS 5 secondary progressive MS.
List of the 65 significantly enriched pathways shared across distinct MS stages and classified according to the main biological categories. Pathways with
relevant scientific evidence of a pathogenic role in MS were provided with PubMed identifiers.
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predisposition to distinct clinical courses of MS, indi-
cating an important role for environmental factors.
Thus, the potential effect of the identified GWAS
genes during distinct stages of MS remains elusive
and needs clarification. As a first step into this direc-
tion, we have verified whether the GWAS genes pos-
tulated by the Immunochip analysis have altered
transcript expression in peripheral mononuclear cells
in MS subjects starting from the early phase of disease
(CIS) to the distinct clinical courses most of the pa-
tients experience. Here, we show that although a core
of GWAS genes is concordantly dysregulated in all
MS stages when compared with the healthy popula-
tion, each disease group is characterized by a distinct
set of dysregulated GWAS genes, clearly indicating
that alteration in the expression of MS risk genes is
not a stable feature reproduced throughout the dis-
tinct phases and forms of disease, but is a selective
event for each disease stage. Notably, 26 MS suscep-
tibility genes were concordantly regulated in 2 inde-
pendent cohorts measured with distinct array
platforms which use different probes to detect gene
expression, emphasizing the robustness of several dys-
regulations. A GWAS DEG in our study was CD86
(B7-2), a costimulatory molecule expressed by a
wide range of leukocytes14 and critically involved
in T-lymphocyte activation and proliferation.15,16
Monocytes of patients with RR-MS display higher
expression of CD86 compared with healthy controls
and interferon b treatment triggers reversal regulation
of CD86.17 Here, we demonstrate the overexpression
of CD86 transcripts in PBMC at all the stages of MS
compared with HCs in 2 independent microarray
data sets and in a third independent cohort using
q-PCR. Further, we report that the expression of
JDP2, MAF, MAPK3, and RGS1 is upregulated in
MS. Of interest, RGS1 is also upregulated by patho-
genic Th17 T cells during experimental autoimmune
encephalomyelitis (EAE).18 Conversely, BACH2,
a critical transcriptional factor regulating the balance
between tolerance and immunity by repressing CD41
T-cell differentiation,19 is downregulated in patho-
genic T cells in EAE mice18 and in the blood of
RR-MS subjects.20 Our study confirms this observa-
tion and extends it to the other MS stages. Very
limited information is present in the literature about
the expression of other GWAS genes in MS blood
cells. A recent report has highlighted the downregu-
lation of the transcription factor EOMES in whole
blood of CIS and a pooled group of MS subjects
with various disease courses compared with HCs
by both RNA-seq and RT-PCR analysis.21 We con-
firm the low transcript levels in CIS but not in the
distinct clinical forms when analyzed separately.
Furthermore, our study dissects the previously re-
ported differential regulation of IKZF3, FOXP1,
ZNF438 in CIS, and all MS clinical forms21 and
reproduces IL7R downregulation in PP-MS.22
The regulation of the other GWAS genes during
MS finds the first description in our study. Concern-
ing the frequency of dysregulation of MS suscepti-
bility genes, a recent work shows that CD4-positive
pathogenic T cells during EAE are significantly en-
riched in dysregulated GWAS genes.18 It is impor-
tant that this observation is conserved in human
PBMC, as we demonstrate a significantly high fre-
quency of dysregulated GWAS genes in CIS and
progressive forms of MS but not in RR-MS. As
the potential to find transcriptional dysregulation
in RR-MS data, however, was comparable with that
in CIS (25.68% and 23.67% global dysregulation in
CIS and RR-MS, respectively), the lack of enrich-
ment in GWAS DEG in RR-MS has most probably
a biological reason, whose explanation remains
obscure.
Thus, to our knowledge, we report the first sys-
tematic expression analysis for MS GWAS genes
using large cohorts of untreated subjects with dis-
tinct MS stages and HCs, and describe several novel
GWAS dysregulations, whose single functional ef-
fects on MS pathogenesis deserve further investiga-
tions in appropriate animal models. In addition,
genome-wide expression profiling has provided rele-
vant information about the overall quality and fre-
quency of dysregulation in PBMC transcriptomes
at distinct MS stages. Previous studies have searched
for pathways in MS using the full list of GWAS
genes under the assumption that all GWAS genes
are dysregulated in MS in all tissues and at all disease
stages.23,24 Our study demonstrates that this hypoth-
esis may be wrong, as MS GWAS genes are not all
dysregulated at the transcriptional level in PBMC
and that there may be differences among disease
courses. To investigate the combined effects of mul-
tiple dysregulations, we have searched for biological
processes significantly enriched in DEG, including
MS risk genes, as we have considered that MS is not
a pure genetic disorder and pathogenic pathways
may be contributed by transcriptional dysregulation
determined by environmental factors as well. We
report here the complete list of pathways obtained
for each disease stage. Notably, several of them were
detected in single forms of disease, whereas others
were common to more than 1 MS stage with 65
pathways appearing in all the distinct MS subtypes.
The shared pathways involve well-known functions
in MS pathogenesis as cell signaling and migration,
immunity, and apoptosis. Scientific evidence about
a pathogenic role for most of these shared pathways
is already available in the literature; however the
contribution of the single pathways to the distinct
MS stages still needs to be clarified. Furthermore, we
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describe a series of novel candidate pathogenic path-
ways inMS, which deserve investigation and validation.
Overall, we offer the scientific community a large
transcriptomic data set for expression studies in MS,
the evidence about dysregulation of several known
MS risk genes in blood at distinct MS stages, and
the complete list of significant pathways contributed
by GWAS genes for each disease form. This informa-
tion may serve as the basis for novel translational
medicine studies investigating the molecular frame-
work underlying MS pathogenesis.
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